CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
OPERATING ACTIVITIES
Net loss	$ (1,191)	$ (1,256)
Non cash items:
Amortization	144	134
Non-cash stock-based compensation	0	32
Change in other operating items:
Other current assets	25	152
Accounts payable	(92)	71
Other accrued liabilities	(19)	37
Cash flows used in operating activities	(1,133)	(830)
INVESTING ACTIVITIES
Cash flows provided by investing activities	0	0
FINANCING ACTIVITIES
Sale of Commmon Stock	1,013	0
LipimetiX Development, Inc. Series B-1 Preferred Stock, net of issuance costs of $66	0	946
Pay-off of Convertible Promissory Notes	(1,000)	0
Issuance of Secured Debt, net of issuance costs of $287	2,140	0
Cash flows provided by financing activities	2,153	946
NET DECREASE IN CASH AND CASH EQUIVALENTS	1,020	116
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	698	1,011
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 1,718	$ 1,127